A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.
Trial details
- Registry ID
- NCT05288504
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as CERC-002, AEVI-002, MDGN-002
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.NCT05288504 | AVTX | Phase 2 | Completed | 2023-05-11Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |